MedTrace Logo

Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

NCT02307279 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 436

Last updated 2022-08-30

Study results available
· View outcomes & findings →

Summary

This study will asses the decrease in body weight after repeated administration of Gelesis100 in overweight and obese subjects with and without Type 2 Diabetes.

Conditions

Interventions

DEVICE

Gelesis100

DEVICE

placebo

Sponsors & Collaborators

  • Gelesis, Inc.

    lead INDUSTRY

Principal Investigators

  • Hassan M Heshmati, MD · Chief Medical Officer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2017-06-30
Completion
2017-06-30
FDA Device
Yes

Countries

  • United States
  • Canada
  • Czechia
  • Denmark
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02307279 on ClinicalTrials.gov